Caroline Nebhan, MD, PhD


Dr. Nebhan on the Efficacy of Checkpoint Inhibitors in Older Patients With Cancer

Caroline Nebhan, MD, PhD, discusses the efficacy of checkpoint inhibitors in older patients with cancer.

Daniel Sherbenou, MD, PhD


Dr. Sherbenou on Selecting Treatment in Late Relapsed Multiple Myeloma

Daniel Sherbenou, MD, PhD, discusses selecting between available treatment options for patients with late relapsed multiple myeloma.

Jared Kaltwasser


For Staudt, a Keen Eye Sparks Opportunities to Dig Deeper

Driven by his twin passions for music and science, Louis M. Staudt, MD, PhD, has made a career out of reading between the notes.

Kevin Diasti, MD


Geography Should Not Be Destiny

To really advance equity in cancer care, we must think long and hard about where we apply innovation and how we measure success.

Andrei Gafita, MD


Dr. Gafita on Prognostic Models for Treatment With 177Lu-PSMA-617 in mCRPC

Andrei Gafita, MD, discusses key takeaways from a retrospective analysis evaluating lutetium-177 PSMA-617 in patients with metastatic castration-resistant prostate cancer.

Steven J. Cohen, MD


Dr. Cohen on the Importance of Obtaining an Adequate Tissue Sample in GI Malignancies

Steven J. Cohen, MD, discusses the importance of obtaining an adequate tissue sample for molecular testing in gastrointestinal cancers.

Anne Chiang, MD, PhD, Yale Cancer Center


Dr Chiang on Managing Advanced NSCLC Without Driver Mutations

Anne Chiang, MD, PhD, discusses treating patients with advanced non–small cell lung cancer without driver mutations.

Ryan D. Cassaday, MD, University of Washington/Fred Hutch


On the Horizon: Exciting Prospects in the Acute Lymphoblastic Leukemia Treatment Landscape

Closing thoughts from a panel of ALL experts on improving access to therapy and how their field may evolve in years to come.

Brandon Blue, MD


Dr. Blue on the Importance of Early Intervention in Relapsed/Refractory Multiple Myeloma

Brandon Blue, MD, discusses the importance of early intervention in relapsed/refractory multiple myeloma.

Ernest S. Han, MD, PhD


Dr Han on the Use of HIPEC in Ovarian Cancer

Ernest S. Han, MD, PhD, discusses the use of hyperthermic intraperitoneal chemotherapy in ovarian cancer.

Praveen Ramakrishnan, MD, MS


Dr. Ramakrishnan on the Evolving Landscape of CAR T-cell Therapy in DLBCL

Praveen Ramakrishnan, MD, MS, discusses the evolving landscape of CAR T-cell therapy in diffuse large B-cell lymphoma.

Stephen Freedland, MD, Cedars-Sinai Medical Center


Advanced Prostate Cancer: Remaining Challenges

Experts discuss challenges and unmet needs in men with advanced prostate cancer who are undergoing treatment with androgen deprivation therapy.

Wenxin Xu, MD


Dr Xu on Changes in Systemic Therapy in RCC

Wenxin (Vincent) Xu, MD, on evolving systemic therapy and the utilization of biomarkers in the treatment of renal cell carcinoma.

Bradley J. Monk, MD, FACS, FACOG


Adverse Events Associated With Immunotherapy in the Treatment of Endometrial Cancer

Christian Marth, MD, PhD, reviews the adverse effects of pembrolizumab and lenvatinib in the treatment of endometrial cancer, as well as the patient experience with these treatments.

Navid Redjal, MD, FAANS


Dr. Redjal on Technological Advances in Neurosurgical Oncology

Navid Redjal, MD, FAANS, discusses technological advances that have impacted neurosurgical oncology.

Steven Vernino, MD, PhD


Clinical Pearls and the Future of LEMS

Experts provide clinical pearls on treating Lambert-Eaton myasthenic syndrome and small cell lung cancer and share upcoming advances and trials they look forward to.

Mansi Dalal, MD


Dr. Dalal on Graft Failure in Pediatric Non-malignant Disorders

Mansi Dalal, MD, discusses findings from a study investigating graft failure risk factors in pediatric patients receiving allogeneic hematopoietic stem cell transplant for non-malignant disorders.

Turab J Mohammed, MD


Dr Mohammed on the Challenges of Diagnosing BPDCN

Turab J. Mohammed, MD, discusses challenges associated with the diagnosis of blastic plasmacytoid dendritic cell neoplasm, and strategies to improve early diagnosis of this disease.

Volkmar Mueller, MD, Prof Dr, University Medical Center Hamburg-Eppendorf


Addressing Treatment Gaps in HER2+ MBC

Unmet needs regarding the selection and sequencing of therapies for patients with HER2-positive metastatic breast cancer.

Theresa Boyle, MD, PhD


Dr. Boyle on Approaching Biomarker Testing in Lung Cancer

Theresa Boyle, MD, PhD, discusses the current approach to biomarker testing in lung cancer.

Ahmed Elkhanany, MD


Dr Elkhanany on Biological Drivers of Progression in ER+ Metastatic Breast Cancer

Ahmed Elkhanany, MD, discusses biological drivers of disease in patients with estrogen receptor–positive breast cancer who have disease progression shortly after initiating first-line therapy, as well as the importance of performing comprehensive genetic testing in these patients to determine subsequent treatment approaches. 

Paul Szabolcs, MD


Rapid Readout: HSCT With Omidubicel Achieved Robust Immune Reconstitution and Lower Rates of Severe Infection Compared to UCB Transplantation

Expert hematologist/oncologist Paul Szabolcs, MD, reviews positive data from a clinical trial comparing hematopoietic stem cell transplantation and omidubicel with standard cord blood transplantation.

Allina Health


Allina Health Cancer Institute Begins First-of-its-Kind Clinical Trial to Revolutionize Cancer Treatment and Diagnosis

Allina Health Cancer Institute is collaborating with St. Paul-based Astrin Biosciences for a first-of-its-kind clinical trial using artificial intelligence and a simple blood draw to revolutionize how cancer is diagnosed and treated.

Warren Fingrut, MD


Dr. Fingrut on the Association Between Ancestry, Socioeconomic Status, and HLA-Disparate Grafts

Warren Fingrut, MD, discusses the association between non-European ancestry and low socioeconomic status with the receipt of HLA-disparate grafts.

Aileen I. Fernandez, PhD


Dr. Fernandez on the Utility of Trastuzumab Deruxtecan in HER2-Low Breast Cancer

Aileen I. Fernandez, PhD, discusses the utility of fam-trastuzumab deruxtecan-nxki in HER2-low breast cancer.

Prakash Pandalai, MD


Dr. Pandalai on Outcomes With Adjuvant HIPEC in CRC

Prakash Pandalai, MD, discusses outcomes with adjuvant hyperthermic intraperitoneal chemotherapy in patients with colorectal cancer.

Marty Trieschmann


UAMS Breast Cancer Program Earns National Reaccreditation

The Breast Cancer program at the University of Arkansas for Medical Sciences Winthrop P. Rockefeller Cancer Institute has earned reaccreditation from the National Accreditation Program for Breast Centers.

Karen L. Klugo, MD


BCMA-Targeting Therapies for RRMM: Future Perspectives

Considerations for optimizing treatment with BCMA-targeting agents for patients with relapsed/refractory multiple myeloma moving forward.

Katharina Hoebel, MD, PhD


Dr Hoebel on Modeling Spatial Interactions to Predict Outcomes in NSCLC

Katharina Hoebel, MD, PhD discusses the efficacy of incorporating spatial interactions within predictive models, in the realm of oncology.